OnCARlytics combines cf33 to express cd19 on cancer cell walls, so that CD19 CAR T can target solid tumours.
They've just licenced a Cd19 CAR T.
we big pharma now
Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-22
-
- There are more pages in this discussion • 485 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
-0.001(0.85%) |
Mkt cap ! $440.9M | |||
| Open | High | Low | Value | Volume |
| 6.0¢ | 6.2¢ | 5.8¢ | $1.284M | 21.33M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 1361156 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 312964 | 21 |
View Market Depth
| Last trade - 11.55am 15/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |